Release Details

Paris, December 19th 2016 - ABIVAX (Euronext Paris : FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today provides its planned financial calendar for 2017, which is set as follows:

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section (www.abivax.com/en).